Dominik P. Modest, MD, on Colorectal Cancer: Health-Related Quality-of-Life Findings From CodeBreaK 300
2024 ASCO GI Cancers Symposium
Dominik P. Modest, MD, of Charité-Universitätsmedizin Berlin, discusses phase III study findings showing sotorasib plus panitumumab vs trifluridine/tipiracil or regorafenib benefits patients with chemorefractory metastatic colorectal cancer in terms of improved clinical outcomes and better self-reported quality of life (Abstract 10).
The ASCO Post Staff
Ian Chau, MD, of The Royal Marsden Hospital, discusses an analysis from the CheckMate 648 study on quality-adjusted time without symptoms and toxicity in patients with unresectable advanced esophageal squamous cell carcinoma. Patients treated with nivolumab plus ipilimumab and nivolumab plus chemotherapy compared with chemotherapy alone experienced longer quality-adjusted survival (Abstract 251).
The ASCO Post Staff
Frank Kullmann, MD, of Germany’s Klinikum Weiden, discusses results from the ALPACA trial, which suggest a dose-reduced regimen with alternating cycles of gemcitabine/nab-paclitaxel and gemcitabine monotherapy after three induction cycles of standard gemcitabine/nab-paclitaxel is feasible and associated with an overall survival comparable to that with standard treatment, as well as improved tolerability (Abstract 605).
The ASCO Post Staff
Milind M. Javle, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II results on tinengotinib, a next-generation FGFR inhibitor that seems to overcome acquired resistance and shows efficacy in patients with cholangiocarcinoma with other FGFR alterations who are not eligible for FGFR2-targeted treatments. A phase III global study is currently enrolling to further evaluate the efficacy and safety of this agent vs physician’s choice in FGFR-altered, chemotherapy- and FGFR-inhibitor–refractory or relapsed disease.
The ASCO Post Staff
Ken Kato, MD, PhD, of Japan’s National Cancer Center Hospital, discusses the first comprehensive findings on biomarkers from the CheckMate 648 study. These results further corroborate the clinical efficacy of nivolumab plus chemotherapy and nivolumab plus ipilimumab in the first-line treatment of advanced esophageal squamous cell carcinoma. According to Dr. Kato, the data suggest an overall survival benefit across multiple biomarker subgroups (Abstract 252).
The ASCO Post Staff
Anant Ramaswamy, DM, of Tata Memorial Centre, discusses phase III results of a study that added docetaxel to a doublet regimen of fluorouracil or capecitabine and oxaliplatin, which did not improve overall survival in patients with advanced gastroesophageal junction and gastric cancers. Continuing chemotherapy beyond 6 months also did not appear to improve survival in this population (Abstract LBA248).
